Regulation and regulatory activities of transforming growth factor β

Critical Reviews in Eukaryotic Gene Expression

Volumn 9, Issue 1, 1999, Pages 33-44

  Bonewald, Lynda F ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cancer; Fibrosis; Latency; Latent TGF binding protein; Osteoporosis; TGF receptors; Transforming growth factor

Indexed keywords

BINDING PROTEIN; ISOPROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

BINDING AFFINITY; CANCER; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION REGULATION; GENE TARGETING; GROWTH INHIBITION; HUMAN; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033367321     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/critreveukaryotgeneexpr.v9.i1.30     Document Type: Review

References (93)

1. Bonewald LF (1996): Transforming growth factor-β. In Bilezikian J, Raisz L, Rodan G (eds): "Principles of Bone Biology." San Diego: Academic Press, pp. 647-659.
2. Bonewald LF, Dallas S (1994): Role of active and latent transforming growth factor β in bone formation. J Cell Biochem 55:350-357.
3. Bonewald LF, Wakefield L, Oreffo ROC, Escobedo A, Twardzik DR, Mundy GR (1991): Latent forms of transforming growth factor-beta (TGFβ) derived from bone cultures. Identification of a naturally occurring 100-kDa complex with similarity to recombinant later TGFβ. Mol Endocrinol 5:741-751.
4. Border WA, Noble NA (1994): Transforming growth factor beta in tissue fibrosis. New Engl J Med 331:1286.
5. 3. J Biol Chem 269:28374-28381.
6. Brown PD, Wakefield LM, Levinson AD, Sporn MB (1990): Physiochemical activation of recombinant latent transforming growth factor β's 1, 2, and 3. Growth Factors 3:35-43.
7. Burmester JK, Qian SW, Ohlsen D, Phan S, Sporn MB, Roberts AB (1998): Mutational analysis of a transforming growth factor-β receptor binding site. Growth Factors 15:231-242.
8. Cannio R, Rennie PS, Blasi F (1993): A cell-type specific and enhancer-dependent silencer in the regulation of the expression of the human urokinase plasminogen activator gene. Nucl Acids Res 19:2303-2308.
9. Carcamo J, Weis FMB, Ventura F, Wieser R, Wrana JL, Attisano L, Massague J (1994): Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor β and activin. Mol Cell Biol (June 1994):3810-3821.
10. Centrella M HM, Wozney JM, McCarthy TL (1994): Transforming growth factor-β gene family members and bone. Endocr Rev 15:27-39.
11. Cheifetz S, Massague J (1986): Cellular distribution of type I and type II receptors for transforming growth factor-β. J Biol Chem 261:9972-9978.
12. Chen R-H, Ebner R, Derynck R (1993): Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities. Science 260:1335-1338.
13. Coffey RJ, Kost LJ, Lyons RM, Moses HL, LaRusso NF (1987): Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. J Clin Invest 80:750-757.
14. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SMF, Lawler J, Hynes RO, Boivin GP, Bouck N (1998): Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 93:1159-1170.
15. Dallas SL, Park-Snyder S, Miyazono K, Twardzik D, Mundy GR, Bonewald LF (1994): Characterization and autoregulation of latent transforming growth factor β (TGFβ) complexes in osteoblast-like cell lines. J Biol Chem 269:6815-6822.
16. Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF (1995): Dual role for the latent transforming growth factor beta binding protein (LTBP) in storage of latent TGFβ in the extracellular matrix and as a structural matrix protein. J Cell Biol 131:539-549.
17. Dallas SL, Saharinen J, Bruder S, Mundy GR, Bonewald LF (1997): Co-localization of the latent TGFβ binding protein-1 (LTBP1) and fibrillin-1 to microfibrils at sites of bone formation. ASBMR 178:8147.
18. Daopin S, Piez KA, Ogawa Y, Davies DR (1992): Crystal structure of transforming growth factor-β2: An unusual fold for the superfamily. Science 257:369-373.
19. de Winter JP, Roelen BAJ, ten Dijke P, van der Burg B, van den Eijnden-van Raaij AJM (1997): DPC4 (SMAD4) mediates transforming growth factorβ1 (TGF-β1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 14: 1891-1899.
20. Derynck R (1994): TGF-β-receptor-mediated signaling. TIBS 19:548-553.
21. Diebold RJ, Eis MJ, Yin M, Ormsby I, Boivin GP, Darrow BJ, Saffitz JE, Doetschman T (1995): Early onset multifocal inflammation in the TGFβ1-null mouse is lymphocyte mediated. Proc Natl Acad Sci USA 92: 12215-12219.
22. Dietz HC, Pyeritz PE (1995): Mutations in the human fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum Mol Genet 4:1799-1809.
23. Eklov S, Funa K, Nordgren H, Olofsson A, Kanzaki T, Miyazono K, Nilsson S (1993): Lack of the latent transforming growth factor beta binding protein in malignant, but not benign prostatic tissue. Cancer Res 53:3193-3197.
24. Erlebacher A, Derynck R (1996): Increased expression of TGF-β2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 132:195-210.
25. Erlebacher A, Filvaroff EH, Ye JQ, Derynck R (1998): Osteoblastic responses to TGF-β during bone remodeling. Mol Biol Cell 9:1903-1918.
26. Filvaroff EH, Erlebacher A, Ye J-O, Gitelman SE, Lotz JC, Heilmann MR, Derynck R (1997): Increased Trabecular Bone in Transgenic Mice Expressing a Truncated, Dominant-Negative, Type II TGF-β Receptor in Osteoblasts. Cincinnati: ASBMR 19th Annual Meeting.
27. Flaumenhaft R, Abe M, Mignatti P, Rifkin DB (1992): Basic fibroblast growth factor-induced activation of latent transforming growth factor β in endothelial cells: Regulation of plasminogen activator activity. J Cell Biol 118:902-909.
28. Flaumenhaft R, Abe M, Sato Y, Miyazono K, Harpel J, Heldin CH, Rifkin DB (1993): Role of the latent TGFβ binding protein in the activation of latent TGFβ by co-cultures of endothelial and smooth muscle cells. J Cell Biol 120:995-1002.
29. Fynan TM, Reiss M (1993): Resistance to inhibitation of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncogenesis 4:493-540.
30. Gazit D, Zilberman Y, Ebner R, Kahn A (1998): Bone loss (osteopenia) in old male mice results from diminished activity and availability of TGF-β. J Cell Biochem 70:478-488.
31. Graycar JL, Miller DA, Arrick BA, Lynnons RM, Moses HL, Derynck R (1989): Human transforming growth β3: Recombinant expression, purification, and biological activities in comparison with transforming growth factor β1 and β2. Mol Endocrinol 3:1977-1876.
32. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce B, Yoneda T, Mundy GR (1996): Evidence for a causal role of parathyroid hormone-related protein in the patho-genesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544-1549.
33. Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996): DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353.
34. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu Y-Y, Grinnell BW, Richardson MA, Topper JN, Gimbrone MA, Wrana JL, Falb D (1997): The MAD-related protein Smad7 associates with the TGF-beta receptor and functions as an antagonist of TGF-beta signaling. Cell 89:1165-1173.
35. Heldin C-H, Miyazono K, ten Dijke P (1997): TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature 390:465-471.
36. Hinck AP, Qian SW, Roberts AB, Sporn MB, Weatherbee JA, Tsang ML-S, Lucas R, Zhang B-L, Wenker J, Torchia DA (1996): Transforming growth factorβ1: Three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factorβ2. Biochemistry 35:8517-8534.
37. Hu PP-C, Datto MB, Wang X-F (1998): Molecular mechanisms of transforming growth factor β signaling. Endocr Rev 19:349-363.
38. Hyytiainen MTJ, Heldin CH, Keski-Oja J (1998): Recombinant latent transforming growth factor-binding protein 2 assembles to fibroblast extracellular matrix and is susceptible to proteolytic processing and release. J Biol Chem 273:20669-20676.
39. Imamura T, Nishihara A, Oede E, Hanai J, Kawabata M, Miyazono K (1997): Smad6 inhibits signalling by the TGF-beta superfamily. Nature 389:622-626.
40. Kanzaki T, Olofsson A, Moren A, Wernstedt C, Hellman U, Miyazono K, Claesson-Welsh L, Heldin CH (1990): TGFβ1 binding protein: A component of the large latent complex of TGFβ1, with multiple repeat sequences. Cell 61:1051-1061.
41. Kerr LD, Miller DB, Matrisian LM (1990): TGF-beta 1 inhibition of transin/stromelysin gene expression is mediated through a Fos binding sequence. Cell 61:267-278.
42. Kielty CM, Shuttleworth CA (1995): Fibrillin-containing microfibrils: structure and function in health and disease. Inter J Biochem & Cell Biol 27:747-760.
43. Kim S-J, Glick A, Sporn MB, Roberts AB (1989): Characterization of the promoter region of the human transforming growth factor-β1 gene. J Biol Chem 264: 402-408.
44. Kim S-J, Park P, Koeller D, Kim KY, Wakefield LM, Sporn MB, Roberts AB (1992): Transforming growth factor-β1: There is regulation beyond transcription. J Biol Chem 267:13702-13707.
45. Kojima S, Rifkin DB (1993): Mechanism of retinoid-induced activation of latent transforming growth factor-β in bovine endothelial cells. J Cell Physiol 155:323-332.
46. Kramer IM, Koornneef I, de Laat SW, van den Eijnden-van Raaij AJ (1991): TGF-beta 1 induces phosphorylation of the cyclic AMP responsive element binding protein in ML-CC164 cells. EMBO J 10:1083-1089.
47. Kulkarni AB, Huh C-G, Backer D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S (1993): Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90: 770-774.
48. Lafyatis RLR, Kim SJ. Jakowlew S, Roberts AB, Sporn MB (1990): Structural and functional characterization of the transforming growth factor β3 promoter. J Biol Chem 265:19128-19136.
49. Langdahl BL, Knudsen JY, Jensen HK, Gregersen N, Eriksen EF (1997): A sequence variation: 713-8deIC in the transforming growth factor-β1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone 20:289-294.
50. Letterio JL, Geiser AG, Kulkarni AB, Roche NS, Sporn MB, Roberts AB (1994): Maternal rescue of transforming growth factor-β1 null mice. Science 264: 1936-1938.
51. Lin HY, Wang X-F, Ng-Eaton E, Weinberg RA, Lodish HF (1992): Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell 68:775-785.
52. Lopez-Casillas F, Wrana JL, Massague J (1993): Betaglycan presents ligand to the TGFβ signaling receptor. Cell 73:1435-1444.
53. Lyons RM, Gentry LE, Puchio AF, Moses HL (1990): Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. J Cell Biol 110:1361-1367.
54. Malipiero U, Holler M, Werner U, Fontana A (1990): Sequence analysis of the promoter region of the glioblastoma derived T cell suppressor factor/transforming growth factor (TGF)-β2 gene reveals striking differences to the TGF-β1 and -β3 genes. Biochem Biophys Res Commun 171:1145-1151.
55. Marra F, Bonewald LF, Park-Snyder S, Park IS, Woodruff K, Abboud HE (1996): Characterization and regulation of the latent transforming growth factor-β complex secreted by vascular pericytes. J Cell Phys 166:537-546.
56. Massague J, Hata A, Liu F (1997): TGF-β signalling through the Smad pathway. Cell Biol 7:187-192.
57. McAllister KA, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Marketl DS, McKinnon WC, Murrell J, McCormick MK, Pericak-Vance MA, Heutink P, Oostra BA, Haitjema T, Westerman CJJ, Porteous ME, Guttmacher AE, Letarte M, Marchuk DA (1994): Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nature Genet 8:345.
58. Mikuni-Takagaki Y, Kakai Y, Satoyoshi M, Kawano E, Suzuki Y, Kawase T, Saito S (1995): Matrix mineralization and the differentiation of osteocyte-like cells in culture. J Bone Miner Res 10:231-242.
59. Miyazono K, Hellman U, Werstedt C, Heldin CH (1988): Latent high molecular weight complex of transforming growth factor beta. J Biol Chem 263:6407-6415.
60. Miyazono K, Thyberg J, Heldin CH (1992): Retention of the transforming growth factor-β1 precursor in the Golgi complex in a latent endoglycosidase H-sensitive form. J Biol Chem 267:5668-5675.
61. Mizoi T, Ohtani H, Miyazono K, Miyazawa M, Matsuno S, Nagura H (1993): Immunoelectron microscopic localization of transforming growth factor beta 1 and latent transforming growth factor beta 1 binding protein in human gastrointestinal carcinomas: qualitative difference between cancer cells and stromal cells. Cancer Res 53:183-190.
62. Moren A, Olofsson A, Stenman G, Sahlin P, Kanzaki T, Claesson-Welsh L, ten Dijke P, Miyazono K, Heldin CH(1994): Identification and characterization of LTBP-2, a novel latent transforming growth factor b binding protein. J Biol Chem 269:32469-32478.
63. Murphy-Ullrich JE, Schultz-Cherry S, Hook M (1992): Transforming growth factor-β complexes with thrombospondin. Mol Biol Cell 3:181-188.
64. Nunes I, Gleizes PE, Metz CN, Rifkin DB (1997): Latent transforming growth factor-β binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-β. J Cell Biol 136:1151-1163.
65. 2 macroglobulin. J Biol Chem 262:14090-14099.
66. Ogawa Y, Schmidt DK, Dasch JR, Chang RJ, Glaser CB (1992): Purification and characterization of transforming growth factor-beta 2.3 and -beta 1.2 heterodimers from bovine bone. J Biol Chem 267:2325-2328.
67. Oreffo ROC, Mundy GR, Seyedin S, Bonewald L (1989): Activation of the bone derived latent TGF beta complex by isolated osteoclasts. Biochem Biophys Res Commun 158:817-823.
68. Oshima M, Oshima H, Taketo MM (1996): TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 179:297-302.
69. Penttinen RP, Kobayashi S, Bornstein P (1988): Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc Natl Acad Sci USA 85:1105-1108.
70. Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, Ding J, Ferguson MW, Doetschman T (1995): Transforming growth factor-beta 3 is required for secondary palate fusion. Nature Genet 11:409-414.
71. Qian SW, Burmester JK, Tsang ML-S, Weatherbee JA, Hinck AP, Ohlsen DJ, Sporn MB, Roberts AB (1996): Binding affinity of transforming growth factor-β for its type II receptor is determined by the C-terminal region of the molecule. J Biol Chem 271:30656-30662.
72. Raghow R, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH (1987): Transforming growth factor-beta increases steady state levels of type 1 procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest 79:1285-1288.
73. Roberts AB, Flanders DC, Kondiah P, Thompson NL, Van Obberghen-Schilling E, Wakefield L, Rossi P, de Combrugghe B, Heine U, Sporn MB (1988): Transforming growth factor β: Biochemistry and roles in embryogenesis, tissue repair, remodeling, and carcino-genesis. Recent Prog Horm Res 44:157-197.
74. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS (1995): Hepatic expression of mature transforming growth factorβ1 in transgenic mice results in multiple fibrotic tissue lesions. Proc Natl Acad Sci USA 92: 2572-2576.
75. Sandler MA, Zhang JN, Westerhausen DR, Billadello JJ (1994): A novel protein interacts with the major transforming growth factor-beta responsive element in the plasminogen activator inhibitor type-1 gene. J Biol Chem 269:21500-21504.
76. Sanford LP, Ormbsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, Cardell EI, Doetschman T (1997): TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 124: 2659-2670.
77. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE (1995): Regulation of transforming growth factor-β activation by discrete sequences of thrombospondin 1. J Biol Chem 270:7304-7310.
78. Schultz-Cherry S, Lawler J, Murphy-Ullrich JE (1994): The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-β. J Biol Chem 269: 26783-26788.
79. Seyedin SM, Thomas TC, Thompson AY, Rosen DM, Piez KA (1985): Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. Proc Natl Acad Sci USA 82:2267-2271.
80. Sherr CJ (1996): Cancer cell cycles. Science 274:1672-1677.
81. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M. Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T (1992): Targeted disruption of the mouse transforming growth factorβ1 gene results in multifocal inflammatory disease. Nature 359:693-699.
82. Staal A, Van Wijnen AJ, Desai RK, Pols HAP, Birkenhager JC, DeLuca HF, Denhardt DT, Stein JL, van-Leeuwen JP, Stein GS, Lian JB (1996): Antagonistic effects of transforming growth factor-β on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamim D response elements. Endocrinology 137:2001-2011.
83. Streuli CH, Schmidhauser C, Kobrin M, Bissell MJ, Derynck R (1993): Extracellular matrix regulates expression of the TGF-beta 1 gene. J Cell Biol 120:253-260.
84. Taipale J, Keski-Oja J (1996): Hepatocyte growth factor releases epithelial and endothelial cells from growth arrest induced by transforming growth factor-beta1. J Biol Chem 271:4342-4348.
85. Taipale J, Saharinen J, Hedman K, Keski-Oja J (1996): Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils. J Histochem Cytochem 44:875-889.
86. Taipale J, Miyazono K, Heldin C-H, Keski-Oja J (1994): Latent transforming growth factorβ1 associates to fibroblast extracellular matrix via latent TGFβ binding protein. J Cell Biol 124:171-181.
87. Taipale J, Saharinen J, Keski-Oja J (1998): Extracellular matrix-associated transforming growth factorβ: Role in cancer cell growth and invasion. "TGF-β in Cancer." Academic Press, 87-134.
88. Tsuji T, Okada F, Yamaguchi K, Nakamura T (1990): Molecular cloning of the large subunit of transforming growth factor β masking protein and expression of the mRNA in various rat tissues. Proc Natl Acad Sci USA 87:8835-8839.
89. Van Obbberghen-Schilling E, Roche NS, Flanders KC, Sporn MB, Roberts AB (1988): Transforming growth factor β1 positively regulates its own expression in normal and transformed cells. J Biol Chem 263: 7741-7746.
90. Wakefield LM, Smith DM, Flanders KC, Sporn MB (1988): Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. J Biol Chem 263:7646-7654.
91. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, Matsumoto K (1995): Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 270:2008-2011.
92. Zhao S, Dallas SL, Peehl D, Cramer S, Bonewald L, Amano S (1997): Prostate-Specific Antigen is a Potent Activator of the 100kDa Latent TGFβ. Cincinatti: ASBMR.
93. Zhou G-HK, Sechrist GL, Periyasamy S, Brattain MG, Mulder KM (1995): Transforming growth factor β isoform-specific differences in interactions with type I and II transforming growth factor βreceptors. Cancer Res 55: 2056-2062.